Table 1.
Characteristics of the Participants at Baseline
| Safety analysis group (n=13) | Efficacy analysis groupa (n=10) | |
|---|---|---|
| Age, years, mean (SD) | 68.1 (6.05) | 68.7 (6.65) |
| Male, n (%) | 10 (77) | 8 (80) |
| Total MDS-UPDRS score, mean (SD) | 39.2 (13.3) | 43.2 (12.2) |
| Motor MDS-UPDRS score, mean (SD) | 22.9 (9.3) | 24.7 (8.9) |
| Disease duration, years, mean (SD) | 6.1 (4.0) | 6.3 (4.5) |
| H&Y, mean (SD) | 1.73 (0.56) | 1.75 (0.59) |
| MoCA, mean (SD) | 28.2 (1.6) | 27.9 (1.6) |
| Levodopa daily dose equivalent,b mean (SD) | 398.3 (331.0) | 443.8 (349.0) |
a
The 10 participants in the Efficacy Analysis Group are a subgroup of the 13 in the Safety Analysis Group. These are the 10 participants that completed the study.
b
Levodopa Daily Dose Equivalent (LE)=immediate release levodopa × 1 + controlled release levodopa × 0.75 + Pramipexole × 100 + Ropinirole × 20 + Rotigotine × 30 + Selegiline × 10.
H&Y, Hoehn and Yahr scale; MDS-UPDRS, Movement Disorder Society Unified Parkinson Disease Rating Scale; MoCA, Montreal Cognitive Assessment.